[ET Net News Agency, 22 October 2021] Shanghai Junshi Biosciences Co., Ltd. (01877)
said Suzhou Kebo Ruijun Biosciences Co., Ltd., a company jointly invested by the company
and Beijing Eirene Biotech Co., Ltd., has received the Acceptance Notice issued by the
National Medical Products Administration. The investigational new drug application for the
JS019 injection (project code: JS019) has been accepted.
The active ingredient of JS019 injection is a recombinant humanised anti-CD39 monoclonal
antibody. CD39 is the enzyme responsible for the initial steps in the conversion of immune
stimulatory extracellular adenosine triphosphate (ATP) to immune suppressive adenosine
(ADO) in the tumour microenvironment, and plays an important role in the immune
suppressive response in the tumour microenvironment. (RC)